Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Mindbio Therapeutics Corp. ( (TSE:MBIO) ) is now available.
MindBio Therapeutics Corp. has successfully completed a non-brokered private placement and debt settlements, raising $92,920 through the issuance of common shares and settling approximately $1.84 million in outstanding debt. This financial maneuver is expected to support the company’s working capital and general corporate purposes, potentially strengthening its position in the biopharmaceutical industry focused on mental health treatments.
More about Mindbio Therapeutics Corp.
MindBio Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on developing novel psychedelic-based medicines for mental health disorders. The company is pioneering the use of microdosing to provide safe, effective, and scalable treatments for conditions such as depression and anxiety, with a mission to improve global mental health outcomes through innovative, evidence-based treatment.
Average Trading Volume: 141,984
Technical Sentiment Signal: Sell
Learn more about MBIO stock on TipRanks’ Stock Analysis page.